In terms of weaknesses, though postmenopausal women are the main target group for osteoporosis treatments such as romososumab, we were only able to examine predicted effects of sclerostin lowering in males and females combined, due to the lack of availability of sex‐specific sclerostin GWAS dataset. Here, SOST is linked to osteoporosis.